Determination of mild, moderate, and severe pain interference in patients with cancer

Pain

Volumn 158, Issue 6, 2017, Pages 1108-1112

  Shi, Qiuling ^a   Mendoza, Tito R ^a   Dueck, Amylou C ^b   Ma, Haijun ^c   Zhang, Jeffrey ^c   Qian, Yi ^c   Bhowmik, Debajyoti ^c   Cleeland, Charles S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c AMGEN INC   (United States)

Author keywords

Assessment; Brief Pain Inventory; Cutpoints; Functioning; Interference; Patient reported outcomes; Severity

Indexed keywords

DENOSUMAB; PLACEBO; ZOLEDRONIC ACID;

ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; BRIEF PAIN INVENTORY; CANCER PAIN; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; EUROQOL 5 DIMENSION QUESTIONNAIRE; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY; FUNCTIONAL DISEASE; FUNCTIONAL STATUS ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD; PAIN SEVERITY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; VISUAL ANALOG SCALE; WALKING; WORK; ADOLESCENT; CLINICAL TRIAL; EXERCISE; MIDDLE AGED; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL; PROCEDURES; PSYCHOLOGY; PSYCHOMETRY; QUALITY OF LIFE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANCER PAIN; EXERCISE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PREVALENCE; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNITED STATES; YOUNG ADULT;

EID: 85019964401     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1097/j.pain.0000000000000890     Document Type: Article

References (38)

1. Anderson KO. Role of cutpoints: why grade pain intensity? PAIN 2005; 113:5-6.
2. Atkinson TM, Andreotti CF, Roberts KE, Saracino RM, Hernandez M, Basch E. The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. Support Care Cancer 2015;23:3645-52.
3. Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol 2014;15:114-22.
4. Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI. Cancer-related fatigue. J Natl Compr Canc Netw 2010;8:904-31.
5. Castel LD, Abernethy AP, Li Y, Depuy V, Saville BR, Hartmann KE. Hazards for pain severity and pain interference with daily living, with exploration of brief pain inventory cutpoints, among women with metastatic breast cancer. J Pain Symptom Manage 2007;34:380-92.
6. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
7. Chow E, Ding K, Parulekar WR, Wong RK, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Nabid A, Ong F, van TG, Babington S, Demas WF, Wilson CF, Brundage M, Zhu L, Meyer RM. Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. Support Care Cancer 2016;24:1617-23.
8. Cleeland CS. The brief pain inventory user guide. 2009. Available at: https://www.mdanderson.org/documents/Departments-and-Divisions/Symptom-Research/BPI-UserGuide.pdf. Accessed April 5, 2017.
9. Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. PAIN 1996;67:267-73.
10. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 1994;23:129-38.
11. Diouf M, Bonnetain F, Barbare JC, Bouche O, Dahan L, Paoletti X, Filleron T. Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist 2015;20:62-71.
12. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von ST, White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008;9:105-21.
13. EuroQol Group. EQ-5D-3L user guide. 2015. Available at: http://www.euroqol.org/fileadmin/user-upload/Documenten/PDF/Folders-Flyers/EQ-5D-3L-UserGuide-2015.pdf. Accessed April 5, 2017.
14. Feng Y, Parkin D, Devlin NJ. Assessing the performance of the EQ-VAS in the NHS PROMs programme. Qual Life Res 2014;23:977-89.
15. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, doubleblind study. Lancet 2011;377:813-22.
16. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS. Effect of enzalutamide on time to first skeletalrelated event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014;15:1147-56.
17. Gilbertson-White S, Aouizerat BE, Jahan T, Paul SM, West C, Schumacher K, Dodd MJ, Rabow M, Abu Raddaha AH, Miaskowski C. Determination of cutpoints for low and high number of symptoms in patients with advanced cancer. J Palliat Med 2012;15:1027-36.
18. Goodwin PJ, Bruera E, Stockler M. Pain in patients with cancer. J Clin Oncol 2014;32:1637-9.
19. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOGACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016;387:2008-16.
20. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, Von MR, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
21. Hong TS, Wo JY, Yeap BY, Ben-Josef E, McDonnell EI, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Goyal L, Murphy JE, Javle MM, Wolfgang JA, Drapek LC, Arellano RS, Mamon HJ, Mullen JT, Yoon SS, Tanabe KK, Ferrone CR, Ryan DP, DeLaney TF, Crane CH, Zhu AX. Multi-institutional phase II study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 2016;34:460-8.
22. Institute of Medicine (US) Committee on Advancing Pain Research CaE. Relieving pain in America: a blueprint for transforming prevention. care, education, and research. Washington, DC: National Academies Press (US), 2012.
23. Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, Sperner-Unterweger B. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 1999;17:2932-40.
24. Kroenke K, Theobald D, Wu J, Tu W, Krebs EE. Comparative responsiveness of pain measures in cancer patients. J Pain 2012;13: 764-72.
25. Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007;10:1338-46.
26. Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decisionmaking about cancer treatments. Stat Med 2000;19:113-32.
27. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 1982;5:649-55.
28. Posternak V, Dunn LB, Dhruva A, Paul SM, Luce J, Mastick J, Levine JD, Aouizerat BE, Hammer M, Wright F, Miaskowski C. Differences in demographic, clinical, and symptom characteristics and quality of life outcomes among oncology patients with different types of pain. PAIN 2016;157:892-900.
29. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. PAIN 1995;61:277-84.
30. Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, Chi KN, Balakumaran A, Wei R, Wang H, Braun A, Fizazi K. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 2015;26:368-74.
31. Snyder CF, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the supportive care needs survey and the QLQ-C30. Qual Life Res 2010;19:837-45.
32. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28: 5132-9.
33. Swarm RA, Abernethy AP, Anghelescu DL, Benedetti C, Buga S, Cleeland C, Deleon-Casasola OA, Eilers JG, Ferrell B, Green M, Janjan NA, Kamdar MM, Levy MH, Lynch M, McDowell RM, Moryl N, Nesbit SA, Paice JA, Rabow MW, Syrjala KL, Urba SG, Weinstein SM, Dwyer M, Kumar R. Adult cancer pain. J Natl Compr Canc Netw 2013;11: 992-1022.
34. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, Bouter LM, de Vet HC. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol 2007;60: 34-42.
35. Wang XS, Zhao F, Fisch MJ, O'Mara AM, Cella D, Mendoza TR, Cleeland CS. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer 2014;120: 425-32.
36. Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: Mapping from two cancerspecific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Making 2015;35:912-26.
37. Zalon ML. Mild, moderate, and severe pain in patients recovering from major abdominal surgery. Pain Manag Nurs 2014;15:e1-12.
38. Zelman DC, Dukes E, Brandenburg N, Bostrom A, Gore M. Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. PAIN 2005;115:29-36.